MAR 18, 2015 09:57 PM PDT

Immunotherapy: New Hope for Patients With Advanced Lung Cancer

In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an infection after undergoing surgery. Suspecting that the immune system played a role in this mysterious response, he tried treating cancer patients with bacteria in an effort to turn on the immune system. Coley's bold experiments largely failed, however, and faded into obscurity as other cancer treatments, such as radiation and chemotherapy, were put into practice.

Coley wasn't wrong-just far ahead of his time. More than a century later, advances in how the immune system can be harnessed to fight cancer have offered new hope to patients with lung cancer. One of the latest immunotherapies to reach the market is a drug called nivolumab (Opdivo), which the FDA recently approved for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).

"‘Groundbreaking' and ‘revolutionary'" often overstate the case, but they truly apply to the impact of the new immunotherapy agents that target the PD-1 pathway for NSCLC," said Naiyer A. Rizvi, MD, of the Herbert Irving Comprehensive Cancer Center and director of thoracic oncology and immunotherapeutics in the Department of Medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Nivolumab restores the immune system's delicate balance by disabling the PD-1 protein on T cells. PD-1 works by suppressing T cell activity, so when this "checkpoint" protein is inhibited, T cells can go about their business.

Dr. Rizvi led a lung cancer trial recently published in Lancet Oncology that was key to approval of nivolumab for squamous lung cancer. "When I first started treating patients with nivolumab in 2008, it was hard to imagine how dramatically this could help patients who were resistant to all of our standard treatments," said Dr. Rizvi. "We have some patients who are still alive many years after taking this drug, with no evidence of cancer. This has never been seen with standard lung cancer treatment."

While some patients with NSCLC respond well to PD-1 inhibitors, others do not. Dr. Rizvi and his colleagues (at Memorial Sloan Kettering Cancer Center) thought that the cancers that had accumulated the most DNA damage were more likely to have worn out the immune system and would likely be helped the most by PD-1 inhibitors.

They tested this by sequencing tumor DNA from both responders and non-responders to treatment with pembrolizumab (Keytruda), a PD-1 inhibitor. Among their findings, published in March in Science, was that patients with a great deal of DNA damage were far more responsive to treatment than those with less DNA damage. "We were able to use advances in sequencing technology to study the entire exome-the protein-coding genes of the genome-of tumors from patients with NSCLC who were treated with pembrolizumab. We found that the more genetically damaged the tumor was, the more likely the patient was to respond to PD-1 inhibitors."

"This is an important first step toward being able to predict who will respond to PD-1 inhibitors and could be a new way to think about precision medicine based on the sequencing of tumor DNA," said Dr. Rizvi. "This collaboration among clinical researchers, geneticists, and immunologists shows how a team of scientists can work together to help patients fight cancer."

Source: Columbia University
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 14, 2018
Health & Medicine
JUN 14, 2018
Fitness Lowers the Risk of Death for Cancer Survivors
It’s no secret that practicing a healthy lifestyle can help you live longer and feel better. Exercise and a nutritious diet are always wise deci...
JUN 25, 2018
Cancer
JUN 25, 2018
B-cell Lymphoma Develops After MPN JAK1/2 Therapy
Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitor therapy are at increased risk of developing aggressive B-cell lymphoma due to pre-existing B-cell clone specifically a...
JUL 10, 2018
Cancer
JUL 10, 2018
TdT Positive Cells - Not Just for Neoplasms
TdT positive cells are associated with early lymphoid neoplasms but healthy lymphoid precursors can also be positive, especially in pediatric patient lymph nodes....
AUG 15, 2018
Cancer
AUG 15, 2018
Cancer Control Headway in The Last 20 Years
Learning from history and what changes have been made will continue to help drive cancer controls for the future....
AUG 21, 2018
Cancer
AUG 21, 2018
'Zombie' gene returns to life and kills cancer in elephants
Researchers have discovered a gene that can protect elephants from cancer. An estimated 17 percent of humans worldwide die from cancer, but less than five ...
SEP 13, 2018
Cancer
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
Loading Comments...